https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38373 80% of 18 samples as having short, medium or long telomeres compared with 33–72% using other methods.]]> Wed 01 Sep 2021 12:47:32 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:989 Sat 24 Mar 2018 08:29:49 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12336 Sat 24 Mar 2018 08:15:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12304 50 values between 0.23 and 7.6 μM. Addition of pyridoxine at concentrations of 1–25 μM does not affect OHP cytotoxicity. Conclusions: Administration of pyridoxine, at concentrations extending across possible therapeutic plasma levels in humans, does not antagonise OHP antitumour effects in a range of relevant tumour cell lines. This study provides a foundation for clinical studies to test whether pyridoxine can minimise OHP-related neurotoxicity, and clinicians can be confident that pyridoxine is very unlikely to reverse the antitumour effects of OHP, as seems to be the case with Ca/Mg infusions. This could prove to be a cost-effective way to minimise OHP-related neurotoxicity, allowing more effective less toxic treatment and better outcomes in patients.]]> Sat 24 Mar 2018 08:11:35 AEDT ]]>